| Study Number | Study Phase | Start Date | Recruitment Status |
| KU36-58 (D0810C00008) | Phase II | 13 Jun 2007 | Active, not recruiting |
| A Phase II open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU-0059436 given orally twice daily in patients with advanced D0810C000BRCA1- or BRCA2-associated ovarian cancer. |
| KU36-44 (D0810C00009) | Phase II | 15 Jun 2007 | Active, not recruiting |
| A Phase II open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU-0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associated breast cancer. |
KU36-73
(D0810C00003) | Phase I | 10 Jan 2007 | Active, not recruiting |
| A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients with Advanced Melanoma who have not previously received systemic chemotherapy |
KU36-92
(D0810C00002) | Phase I | 11 Jul 2007 | Active, not recruiting |
| A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients with Advanced Tumours. |
| KU36-96 (D0810C00004) | Phase I | 28 Jun 2007 | Recruiting
|
| A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination with Carboplatin, KU-0059436 in combination with a Paclitaxel/Carboplatin T/C doublet and KU-0059436 in Combination with Paclitaxel in the Treatment of Patients With Advanced Solid Tumours |
| D0810C00001 | Phase I | 22 Nov 2007 | Recruiting |
| A Phase I, open-label, dose escalation study to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies. |
| D0810C00005 | Phase I | 17 Aug 2007 | Recruiting |
| A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 in combination with Gemcitabine in the Treatment of Patients with Advanced Pancreatic Cancer. |
| D0810C00005 | Phase I | 17 Aug 2007 | Recruiting |
| A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 in combination with Gemcitabine in the Treatment of Patients with Advanced Pancreatic Cancer. |
| D0810C00010 | Phase I | 17 Mar 2008 | Completed |
| Open, Non-randomised, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]- (KU-0059436) in Patients with Advanced or Metastatic Solid Tumours Refractory to Standard Treatments. |
| D0810C00011 | Phase I/II | 25 Jul 2008 | Recruiting |
| Phase I/II randomised, double- blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer |
| D0810C00012 | Phase II | 14 March 2008 | Not yet recruiting |
| A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Three Different Doses of AZD2281 Given Orally Once or Twice Daily and Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Can. |
| D0810C00019 | Phase II | 27 Aug 2008 | Recruiting |
| Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens |
| D0810C00020 | Phase II | 13 May 2008 | Recruiting |
| Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients with Known BRCA or Recurrent High Grade Serous/ Undifferentiated Tubo-Ovarian Carcinoma and in Known BRCA or Triple Negative Breast Cancer to Determine Response Rate and Correlative Markers of Response |
| D0810C00021 | Phase 1/2 | 3 Nov 2008 | Recruiting |
| A Phase I/II, Open Label, Multi-centre Study of AZD2281 Administered Orally in Combination with Cisplatin, to Assess the Safety and Tolerability in Patients with Advanced Solid Tumours, and to Assess Efficacy in the Neoadjuvant Setting for Patients with Triple Negative Breast Cancer |
| D0810C00022 | Phase I | 30 Jun 2008 | Recruiting |
| A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin®) In Patients With Advanced Solid Tumours |
| D0810C00024 | Phase I | 20 Oct 2008 | Recruiting
|
| A phase I, randomised, 2 period cross over study to determine the comparative bioavailability of two different oral formulations of AZD2281 in cancer patients |
| KU36-93 | Phase I | 5 Jul 2007 | Active, not recruiting |
| A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Topotecan in the Treatment of Patients with Advanced Solid Tumours. |